[
  {
    "ts": "2025-11-17T11:00:00+00:00",
    "headline": "High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy",
    "summary": "Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages2 CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human",
    "url": "https://finance.yahoo.com/news/high-dose-regimen-nusinersen-receives-110000395.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "fb7a1da5-776f-3b99-bbe8-663479beceac",
      "content": {
        "id": "fb7a1da5-776f-3b99-bbe8-663479beceac",
        "contentType": "STORY",
        "title": "High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy",
        "description": "",
        "summary": "Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages2 CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human",
        "pubDate": "2025-11-17T11:00:00Z",
        "displayTime": "2025-11-17T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/high-dose-regimen-nusinersen-receives-110000395.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/high-dose-regimen-nusinersen-receives-110000395.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "IONS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T12:30:00+00:00",
    "headline": "Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments",
    "summary": "– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – CAMBRIDGE, Mass. and BEDFORD, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Thera",
    "url": "https://finance.yahoo.com/news/biogen-stoke-therapeutics-announce-publication-123000912.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "55a5fe8e-be40-3e21-b6f0-49283c774c08",
      "content": {
        "id": "55a5fe8e-be40-3e21-b6f0-49283c774c08",
        "contentType": "STORY",
        "title": "Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments",
        "description": "",
        "summary": "– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – CAMBRIDGE, Mass. and BEDFORD, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Thera",
        "pubDate": "2025-11-17T12:30:00Z",
        "displayTime": "2025-11-17T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-stoke-therapeutics-announce-publication-123000912.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-stoke-therapeutics-announce-publication-123000912.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "STOK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T12:30:00+00:00",
    "headline": "Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments",
    "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., November 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today announced the publication of final data from the BUTTERFLY study, a prospective, two-year natural history study in people with Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent",
    "url": "https://finance.yahoo.com/news/stoke-therapeutics-biogen-announce-publication-123000372.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f12d582c-741d-326a-91f6-f8abc4d1e2ca",
      "content": {
        "id": "f12d582c-741d-326a-91f6-f8abc4d1e2ca",
        "contentType": "STORY",
        "title": "Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments",
        "description": "",
        "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., November 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today announced the publication of final data from the BUTTERFLY study, a prospective, two-year natural history study in people with Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent",
        "pubDate": "2025-11-17T12:30:00Z",
        "displayTime": "2025-11-17T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/6dda8cc97d913f35a323ef314fbda951",
          "originalWidth": 480,
          "originalHeight": 223,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7VZl3TCRgqTA5ie1rcFaOw--~B/aD0yMjM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6dda8cc97d913f35a323ef314fbda951.cf.webp",
              "width": 480,
              "height": 223,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fP7K8Dv35M_k1WvAhuWNSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6dda8cc97d913f35a323ef314fbda951.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stoke-therapeutics-biogen-announce-publication-123000372.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stoke-therapeutics-biogen-announce-publication-123000372.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "STOK"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T11:28:56+00:00",
    "headline": "Biogen acquires Alcyone to boost CNS drug delivery",
    "summary": "ThecaFlex DRx is an implantable device designed to improve treatment options for patients with neurological disorders.",
    "url": "https://www.medicaldevice-network.com/news/biogen-acquires-alcyone/",
    "source": "Medical Device Network",
    "provider": "yfinance",
    "raw": {
      "id": "d27ad94f-9f28-318b-9146-9bd2f055557d",
      "content": {
        "id": "d27ad94f-9f28-318b-9146-9bd2f055557d",
        "contentType": "STORY",
        "title": "Biogen acquires Alcyone to boost CNS drug delivery",
        "description": "",
        "summary": "ThecaFlex DRx is an implantable device designed to improve treatment options for patients with neurological disorders.",
        "pubDate": "2025-11-17T11:28:56Z",
        "displayTime": "2025-11-17T11:28:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/medical_device_network_744/33c3132bf77b66d35a8c4513a0771a83",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "Biogen plans to launch the ThecaFlex DRx system after the completion of ongoing clinical trials and regulatory approvals. Credit: Tada Images / Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lnvUTGQC8etH3tOJVygSsg--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/medical_device_network_744/33c3132bf77b66d35a8c4513a0771a83.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xER9M8VhPrFyJqm6bEczkA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/medical_device_network_744/33c3132bf77b66d35a8c4513a0771a83.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Medical Device Network",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.medicaldevice-network.com/news/biogen-acquires-alcyone/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-acquires-alcyone-boost-cns-112856437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-17T13:52:05+00:00",
    "headline": "Biogen Stock: Is Wall Street Bullish or Bearish?",
    "summary": "Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.",
    "url": "https://www.barchart.com/story/news/36160542/biogen-stock-is-wall-street-bullish-or-bearish",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "36b27019-e869-324d-ae07-5b77c7ac799c",
      "content": {
        "id": "36b27019-e869-324d-ae07-5b77c7ac799c",
        "contentType": "STORY",
        "title": "Biogen Stock: Is Wall Street Bullish or Bearish?",
        "description": "",
        "summary": "Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.",
        "pubDate": "2025-11-17T13:52:05Z",
        "displayTime": "2025-11-17T13:52:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/f5247e5a3989d4d6591f1bb750461101",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "Biogen Inc logo on HQ-by Tada Images via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sWhZeTRZc4j7xUp0dLn2bw--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/f5247e5a3989d4d6591f1bb750461101.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p37gAPeJe48hkDM..tt7bg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/f5247e5a3989d4d6591f1bb750461101.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36160542/biogen-stock-is-wall-street-bullish-or-bearish",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-stock-wall-street-bullish-135205569.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]